Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sangamo Therapeutics, Inc.

SGMOQ ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

OTC · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.14

▼ -2.48%

Market Cap $58.54M · Vol 2.20M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$58.54M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

24.68

Momentum

Beta

1.57

vs Market

52W High

$0.77

81.08% below

52W Low

$0.03

383.00% above

Volume

2.20M

Avg 3.12M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.07%

Public shares

Shariah Compliance8 STANDARDS

✗ Sangamo Therapeutics, Inc. (SGMOQ) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SGMOQ pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.20%

-0.70%

-19.03%

-57.40%

YTD

-66.36%

-74.12%

-82.57%

-98.52%

Financials & Valuation

TTM · Annual

Total Revenue	$39.55M
Net Income	$-122,932,000.00
Revenue Growth (YoY)	-77.60%
Gross Margin	100.00%
Operating Margin	-273.07%
Net Profit Margin	-310.81%
ROE	N/A
ROA · ROIC	-153.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.98
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	414.29M

Technical Indicators

50-Day SMA	$0.12
200-Day SMA	$0.26
RSI (14)	24.68
Beta	1.57
52-Week High	$0.77
52-Week Low	$0.03

Volume Today	2.20M
Avg Daily Volume (30D)	3.12M
Relative Volume	0.71x
Volatility (10D)	35.99
Volatility (30D)	94.22
Free Float	99.07%

Analyst Consensus

N/A

Current Price $0.14

Mean Target N/A

52W Low$0.03 52W High$0.77

Current

Target

$0.03 $0.77

Current Analyst target

· 0 analysts

Identifiers

ExchangeOTC

FIGIN/A

ISINUS8006771062

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +4.00% ARGX.BR argenx SE -0.39% ARGX argenx SE -0.21% 2269.HK WuXi Biologics (Cayman) Inc. +5.26% INSM Insmed Incorporated +0.83%

Company Profile

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.